Could a dengue vaccine be safe for autoimmune patients? new trial seeks answers
NCT ID NCT07087912
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 32 times
Summary
This study is testing a live attenuated dengue vaccine (Butantan-DV) in people aged 12–59 with autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are stable and on low or no immune-suppressing drugs. Researchers want to see if the vaccine triggers a good immune response and is safe compared to healthy volunteers. Participants receive one shot and are followed for a year with blood tests and symptom diaries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for JUVENILE IDIOPATHIC ARTHRITIS (JIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital das Clínicas da Faculdade de Medicina da USP
RECRUITINGSão Paulo, São Paulo, 01246-903, Brazil
-
Rheumatology Division, Faculdade de Medicina da USP
RECRUITINGSão Paulo, São Paulo, Brazil
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.